Latest from the
company
Updates, scientific discoveries, event announcements, and milestones from the preclinics team.
EventMeet preclinics Italia at CPHI Milan 2026
preclinics Italia will be at CPHI Milan, 6–8 October 2026, at Stand 8S61. The team brings expertise in custom single-domain antibody discovery and protein engineering — stop by to discuss challenging antigen targets or a flexible development partnership.
ScienceOvercoming low immunogenicity with VacciTag™
Developing robust antibody titers against weak or structurally difficult antigens remains a major preclinical bottleneck. The VacciTag™ platform taps pre-existing tetanus immunity to deliver high titers without harsh adjuvants — with custom antigen design and production from preclinics Italia.
EventMeet us at RNA Horizons 2026 in Munich
preclinics will be at the 3rd RNA Horizons Conference in Munich, 16–18 September. Jonas Füner and José Dinis Faustino look forward to meeting the mRNA community and to three days of exchange on RNA delivery, formulation and therapeutic development.
Eventpreclinics at GV-SOLAS 2026
From 16 to 18 September, the laboratory animal science community comes together in Bonn for the 62nd Annual Meeting of GV-SOLAS. We look forward to scientific discussions and to meeting colleagues and partners from preclinical research in person.
Companypreclinics Italia is now CIR & CII accredited
preclinics Italia is now an accredited R&D service provider under the French Crédit d'Impôt Recherche (CIR) and Crédit d'Impôt Innovation (CII) schemes. Eligible French companies can benefit from up to 30% tax credit on qualifying R&D activities outsourced to preclinics Italia.
ScienceAnalytical support for your oncology research
Your oncology expertise defines the study question. We contribute the analytical part: longitudinal in vivo imaging combined with molecular and pharmacokinetic readouts from the same study.
EventConference flashbacks: ISTH in Paris
A few weeks ago, our colleague Lara Monica attended ISTH, the must-attend global congress for researchers in hemostasis. Beyond catching up with collaborators and clients from around the world, the meeting brought powerful scientific takeaways and proud moments.
PublicationAI-driven VHH discovery meets experimental validation
This publication highlights what we do best at preclinics: bridging computational antibody design with real-world efficacy.
ScienceProtein quantification: is your candidate ready for in vivo?
Protein quantification reveals whether your lead has the potency, target engagement, and efficacy you need — measured in cell lysates, tissue extracts, and biological fluids.
ScienceVaccination studies: measuring the full immune response
Antibody levels alone don't guarantee protection. At preclinics, we support comprehensive immunogenicity profiling for vaccine development, from prime/boost immunization to functional and cellular readouts.
TeamWelcome Dr. Adibeh Rahmani — our new Head of In Vivo Laboratory
Adibeh is a veterinarian with a strong background in translational biomedical research and extensive experience in preclinical animal models, in vivo surgery, and study design.
No posts in this category yet.